TR200103144T2 - Yeni bileşikler - Google Patents

Yeni bileşikler

Info

Publication number
TR200103144T2
TR200103144T2 TR2001/03144T TR200103144T TR200103144T2 TR 200103144 T2 TR200103144 T2 TR 200103144T2 TR 2001/03144 T TR2001/03144 T TR 2001/03144T TR 200103144 T TR200103144 T TR 200103144T TR 200103144 T2 TR200103144 T2 TR 200103144T2
Authority
TR
Turkey
Prior art keywords
compounds
carboxypeptide
pharmaceutically acceptable
new compounds
salts
Prior art date
Application number
TR2001/03144T
Other languages
English (en)
Inventor
Linschoten Marcel
Polla Magnus
Original Assignee
Astrazaneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazaneca Ab filed Critical Astrazaneca Ab
Publication of TR200103144T2 publication Critical patent/TR200103144T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Mevcut bulus (I) formülüne ait bilesiklerle ve bunlarin farmasötik olarak kabul edilen tuzlari ve çözücüleriyle ya da bu tür tuzlarin çözücüleriyle ilgilidir ve söz konusu bilesikler karboksipeptidas U'yu inhibite ettigi için karboksipeptidas U ile iliskili bulunan hastaliklarin önlenmesinde ve tedavi edilebilmesinde kullanilabilmektedir. Öte yanda bulus, bulus bilesiklerinin tedavi amaçli kullanilmasiyla; bu tür yeni bilesiklerin hazirlanmasina yönelik usullerle; en az bir bulus bilesigi ya da bunun farmasötik olarak kabul edilen tuzunu ya da çözüntüsünü etkin bilesen olarak içeren farmasötik bilesimlerle; ve etkin bilesiklerin yukarida belirtilen tibbi kullanima yönelik ilaçlari imalatinda kullanimiyla ilgilidir.
TR2001/03144T 1999-05-03 2000-05-03 Yeni bileşikler TR200103144T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9901572A SE9901572D0 (sv) 1999-05-03 1999-05-03 New compounds

Publications (1)

Publication Number Publication Date
TR200103144T2 true TR200103144T2 (tr) 2004-11-22

Family

ID=20415425

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03144T TR200103144T2 (tr) 1999-05-03 2000-05-03 Yeni bileşikler

Country Status (23)

Country Link
US (2) US7354895B1 (tr)
EP (1) EP1180099A1 (tr)
JP (1) JP4270759B2 (tr)
KR (1) KR20020010631A (tr)
CN (1) CN1358187A (tr)
AR (1) AR028826A1 (tr)
AU (1) AU4447100A (tr)
BR (1) BR0010256A (tr)
CA (1) CA2371215A1 (tr)
CZ (1) CZ20013931A3 (tr)
EE (1) EE200100573A (tr)
HK (1) HK1042493A1 (tr)
HU (1) HUP0202379A3 (tr)
IL (1) IL145953A0 (tr)
IS (1) IS6141A (tr)
MX (1) MXPA01011043A (tr)
NO (1) NO20015374D0 (tr)
PL (1) PL356140A1 (tr)
SE (1) SE9901572D0 (tr)
SK (1) SK15662001A3 (tr)
TR (1) TR200103144T2 (tr)
WO (1) WO2000066550A1 (tr)
ZA (2) ZA200108966B (tr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100681632B1 (ko) * 1999-09-14 2007-02-09 메이지 세이카 가이샤 리미티드 카르복시펩티다아제 ｂ 저해활성을 갖는 포스폰산 유도체
PL361054A1 (en) * 2000-08-17 2004-09-20 Pfizer Inc. Substituted imidazoles as tafia inhibitors
SE0103272D0 (sv) 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
WO2003061653A1 (en) 2002-01-22 2003-07-31 Pfizer Limited 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases
US6713496B2 (en) 2002-01-22 2004-03-30 Pfizer Inc 3-(imidazolyl)-2-alkoxypropanoic acids
EP1467731A1 (en) * 2002-01-22 2004-10-20 Pfizer Limited 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
EP1497300A2 (en) * 2002-03-21 2005-01-19 Schering Aktiengesellschaft Plasma carboxypeptidase b inhibitors
NZ592764A (en) 2008-10-29 2012-08-31 Taisho Pharmaceutical Co Ltd Compound having tafia inhibitory activity
CN113395996B (zh) 2019-02-08 2024-05-28 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
CN111110837B (zh) * 2020-01-06 2022-11-25 中国人民解放军陆军军医大学 一种羧肽酶抑制剂在制备预防重症致死性轮状病毒感染药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2516307A (en) * 1949-01-06 1950-07-25 Gen Mills Inc Vinyl resins plasticized with cyano esters
US4560680A (en) * 1982-03-15 1985-12-24 E. R. Squibb & Sons, Inc. Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors
US4849414A (en) * 1986-06-11 1989-07-18 E. R. Squibb & Sons, Inc. Substituted aminoalkanoylaminoalkyl phosphonate angiotensin converting enzyme inhibitors
FR2610951B1 (fr) * 1987-02-17 1989-05-05 Aerospatiale Armature tissee pour materiau composite
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
JPH07502507A (ja) * 1991-12-17 1995-03-16 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
US5550119A (en) * 1995-03-02 1996-08-27 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives as ECE inhibitors
US5672592A (en) * 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
JP3440305B2 (ja) * 1997-04-02 2003-08-25 高砂香料工業株式会社 ７−（ｎ−置換アミノ）−２−フェニルヘプタン酸 エステル誘導体及び該誘導体の製造方法
PT973512E (pt) 1997-02-27 2004-07-30 Wyeth Corp N-hidroxi-2-(alquil, aril ou heteroaril sulfanil, sulfinilou sulfonil)-alquil, aril ou heteroarilamidas substituidas na posicao 3 como inibidores de metaloproteinases da matriz
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
SE9901573D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
KR100681632B1 (ko) * 1999-09-14 2007-02-09 메이지 세이카 가이샤 리미티드 카르복시펩티다아제 ｂ 저해활성을 갖는 포스폰산 유도체

Also Published As

Publication number Publication date
JP2002543179A (ja) 2002-12-17
MXPA01011043A (es) 2002-06-04
JP4270759B2 (ja) 2009-06-03
CA2371215A1 (en) 2000-11-09
SE9901572D0 (sv) 1999-05-03
EE200100573A (et) 2003-02-17
AR028826A1 (es) 2003-05-28
SK15662001A3 (sk) 2002-09-10
ZA200108967B (en) 2003-01-30
CN1358187A (zh) 2002-07-10
US7354895B1 (en) 2008-04-08
NO20015374L (no) 2001-11-02
WO2000066550A8 (en) 2001-01-25
HK1042493A1 (zh) 2002-08-16
ZA200108966B (en) 2003-01-30
EP1180099A1 (en) 2002-02-20
KR20020010631A (ko) 2002-02-04
WO2000066550A1 (en) 2000-11-09
HUP0202379A3 (en) 2003-04-28
IL145953A0 (en) 2002-11-10
IS6141A (is) 2001-11-01
HUP0202379A2 (hu) 2002-12-28
BR0010256A (pt) 2002-02-13
AU4447100A (en) 2000-11-17
US20060079484A1 (en) 2006-04-13
CZ20013931A3 (cs) 2002-04-17
PL356140A1 (en) 2004-06-14
NO20015374D0 (no) 2001-11-02
US7423012B2 (en) 2008-09-09

Similar Documents

Publication Publication Date Title
SE9901573D0 (sv) New compounds
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
GEP20043324B (en) Purine Derivatives
DE69931159D1 (de) Antimikrobielle zusammensetzungen enthaltend taurolidin, zitronensäure und natriumzitrat
DK0503440T3 (da) Sumatriptanholdige lægemidler
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
ATE232862T1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
ES2183839T3 (es) Composiciones y procedimiento de reparacion y de prevencion de lesiones del tipo de fibrosis.
SE9900961D0 (sv) Novel compounds
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
DE69333387D1 (de) Pharmazeutische Zusammensetzungen enthaltend Norastemizol.
TR200103144T2 (tr) Yeni bileşikler
SE0002476D0 (sv) New compounds
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
HU9802897D0 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
IE780217L (en) 1,3,5-triazine-2,6-dione derivatives
CA2382654A1 (en) Novel a-500359 derivatives
KR980002033A (ko) 트리아졸 유도체 또는 그 염
DE60233578D1 (de) Phosphorenthaltende Verbindugnen mit antithrombitische Wirkung
SE0301698D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ECSP055804A (es) Composición farmacéutica